Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Naloxone Pharmacokinetics Using Marketed Devices
NCT03386591Phase 1Completed
- Sponsor
- National Institute on Drug Abuse
- Start
- Jan 2018
- Primary completion
- Feb 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of naloxone in opioid overdose (5 arms), sponsored by National Institute on Drug Abuse. Primary endpoints: Maximum Plasma Concentration at 11 days, Area Under the Curve at 11 days and 2 more. Started Jan 2018; status: completed.
02
Drugs
naloxone
03
Conditions
opioid overdose
Beyond the preview
Go deeper on NCT03386591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386591.